Detecting change-points in preclinical rheumatoid arthritis biomarkers using Bayesian multivariate segmented regression

Background

Rheumatoid arthritis (RA) has a preclinical period characterised by elevations in serum autoantibodies. Identifying the timing and magnitude of autoantibody trajectory changes may inform screening strategies and preventative interventions.

Methods

Using a Bayesian multivariate segmented regression, we jointly modelled longitudinal autoantibody trajectories from two Department of Defense Serum Repository cohorts (Sample A: 209 matched case–control pairs, 1566 samples, six biomarkers; Sample B: 309 cases with two matched controls each, 2758 samples, eight biomarkers). Change-points and magnitudes of change were estimated simultaneously under a multivariate likelihood with an unstructured residual correlation matrix.

Results

In Sample A, five of six biomarkers exhibited pre-diagnostic trajectory shifts with 95% highest posterior density intervals excluding zero. RF-IgM demonstrated the earliest change-point at 8.10 years before diagnosis (95% HPDI: −10.47, −5.73), followed by ACPA-IgG at 7.43 years (95% HPDI: −9.33, −5.76). In Sample B, only the four IgG isotypes showed pre-diagnostic shifts, with anti-CCP3 (IgG) earliest at 7.00 years (95% HPDI: −8.48, −5.29). A composite metric integrating timing and magnitude reordered rankings.

Conclusions

This Bayesian framework enables simultaneous estimation of change-points and magnitudes across correlated autoantibodies while fully characterising uncertainty, offering a complementary approach to prior divergence-based methods for understanding preclinical RA autoimmunity.

Key Messages

• We fit a Bayesian multivariate segmented regression to jointly estimate unknown change-points and magnitudes of change across correlated autoantibody trajectories in preclinical rheumatoid arthritis.

• RF-IgM and ACPA-IgG exhibited the earliest pre-diagnostic trajectory acceleration (approximately eight and 7.4 years before diagnosis, respectively), and only IgG isotypes showed consistent pre-diagnostic shifts in a novel panel of anti-citrullinated protein antibodies.

• A composite metric integrating both the timing and magnitude of autoantibody change provides a different ranking of biomarkers than change-point estimation alone, which may inform future screening and prevention strategies.